Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks

Alessandra Marchesi, Isabella Tarissi De Jacobis, Donato Rigante, Alessandro Rimini, Walter Malorni, Giovanni Corsello, Grazia Bossi, Sabrina Buonuomo, Fabio Cardinale, Elisabetta Cortis, Fabrizio De Benedetti, Andrea De Zorzi, Marzia Duse, Domenico Del Principe, Rosa Maria Dellepiane, Livio D'Isanto, Maya El Hachem, Susanna Esposito, Fernanda Falcini, Ugo GiordanoMaria Cristina Maggio, Savina Mannarino, Gianluigi Marseglia, Silvana Martino, Giulia Marucci, Rossella Massaro, Christian Pescosolido, Donatella Pietraforte, Maria Cristina Pietrogrande, Patrizia Salice, Aurelio Secinaro, Elisabetta Straface, Alberto Villani

Research output: Contribution to journalReview article

Abstract

This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications.

Original languageEnglish
Article number103
JournalItalian Journal of Pediatrics
Volume44
Issue number1
DOIs
Publication statusPublished - Aug 30 2018

Keywords

  • Aspirin
  • Child
  • Coronary artery abnormalities
  • Innovative biotechnologies
  • Intravenous immunoglobulin
  • Kawasaki disease
  • Personalized medicine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks'. Together they form a unique fingerprint.

  • Cite this